MAGE family member D4Genealiases: MAGE-D4 · MAGE-E1 · MAGE1
Q-omics provides the consensus-scored MAGED4 profile across patient tissues and cancer cell-line models. MAGED4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MAGED4 is differentially expressed in 7, with the highest sampling consensus in KIRP. Additionally, MAGED4 RNA expression shows 10,094 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KICH, KIRP, and ESCA as cancer lineages where MAGED4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAGED4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAGED4 survival associations across molecular data types. MAGED4 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAGED4 RNA expression–survival associations across cancer types. High MAGED4 expression shows unfavorable associations in KICH, STAD, ACC and LGG, but favorable associations in LUSC and BLCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MAGED4 RNA expression.
This table summarizes MAGED4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for MAGED4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAGED4 shows lower tumor expression in THCA and higher tumor expression in KIRP, HNSC, LUSC, LIHC and LUAD. The KIRP box plot shows higher MAGED4 RNA expression in tumor versus normal tissue (log2 FC = +0.008, t-test p < 0.001).
This table shows molecular features associated with MAGED4 in patient tissues and cancer cell lines. In patient samples, MAGED4 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, MAGED4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
